Targeting the epidermal growth factor receptor: prognostic and clinical implications
- 31 October 2003
- journal article
- Published by Elsevier in European Journal of Cancer Supplements
- Vol. 1 (8) , 9-15
- https://doi.org/10.1016/s1359-6349(03)80015-0
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2003
- Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumorsAnnals of Oncology, 2003
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor TypesJournal of Clinical Oncology, 2002
- Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- ZD1839, a Selective Oral Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor, Is Well Tolerated and Active in Patients With Solid, Malignant Tumors: Results of a Phase I TrialJournal of Clinical Oncology, 2002
- EGFR and cancer prognosisPublished by Elsevier ,2001
- Oncogenic kinase signallingNature, 2001
- Evidence for the differential expression of a variant EGF receptor protein in human prostate cancerBritish Journal of Cancer, 2000
- Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer TherapyDrugs, 2000
- Growth Factors and CancerScience, 1991